Literature DB >> 16093455

SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS.

J H Veldink1, S Kalmijn, A H Van der Hout, H H Lemmink, G J Groeneveld, C Lummen, H Scheffer, J H J Wokke, L H Van den Berg.   

Abstract

BACKGROUND: ALS is believed to be multifactorial in origin with modifying genes affecting its clinical expression. Childhood-onset spinal muscular atrophy (SMA) is an autosomal recessive disorder of motor neurons, caused by mutations of the survival motor neuron (SMN) gene. The SMN gene exists in two highly homologous variants: SMN1, the causative gene responsible for the production of the majority of functional SMN protein, and SMN2, responsible for the production of less protein but sufficient for modifying the SMA phenotype.
OBJECTIVE: To test whether SMN genotypes are associated with susceptibility to and severity of sporadic ALS.
METHODS: We performed competitive quantitative PCR analysis for both SMN1 and SMN2 genes in 242 clinically well-defined ALS patients and 175 controls. The combined determination of SMN1 and SMN2 copies also allowed for an estimation of the level of SMN for each patient (estimated SMN protein level = SMN1 copy number + 0.20 x SMN2 copy number).
RESULTS: One copy of SMN1 was associated with an increased risk of developing ALS (odds ratio = 4.1, 95% CI = 1.2 to 14.2, p = 0.02) and ALS patients carried fewer SMN2 copy numbers (p < 0.001). Sixty-one percent of patients had an estimated protein SMN level < or = 2.2 vs only 36% of controls (p = 0.0000004). Multivariate Cox regression analyses showed that lower SMN2 copy numbers and lower levels of estimated SMN protein (hazard ratio = 1.3, 95% CI = 1.1 to 1.6, p = 0.03) were associated with an increased mortality rate.
CONCLUSIONS: SMN genotypes producing less SMN protein increase susceptibility to and severity of ALS.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16093455     DOI: 10.1212/01.wnl.0000174472.03292.dd

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  34 in total

Review 1.  RNA processing pathways in amyotrophic lateral sclerosis.

Authors:  Marka van Blitterswijk; John E Landers
Journal:  Neurogenetics       Date:  2010-03-27       Impact factor: 2.660

2.  Homozygous SMN2 deletion is a protective factor in the Swedish ALS population.

Authors:  Philippe Corcia; Caroline Ingre; Helene Blasco; Rayomand Press; Julien Praline; Catherine Antar; Charlotte Veyrat-Durebex; Yves-Olivier Guettard; William Camu; Peter M Andersen; Patrick Vourc'h; Christian R Andres
Journal:  Eur J Hum Genet       Date:  2012-01-25       Impact factor: 4.246

Review 3.  Clinical genetics of amyotrophic lateral sclerosis: what do we really know?

Authors:  Peter M Andersen; Ammar Al-Chalabi
Journal:  Nat Rev Neurol       Date:  2011-10-11       Impact factor: 42.937

Review 4.  Genetics of Amyotrophic Lateral Sclerosis.

Authors:  Mehdi Ghasemi; Robert H Brown
Journal:  Cold Spring Harb Perspect Med       Date:  2018-05-01       Impact factor: 6.915

5.  Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers.

Authors:  Marka van Blitterswijk; Bianca Mullen; Michael G Heckman; Matthew C Baker; Mariely DeJesus-Hernandez; Patricia H Brown; Melissa E Murray; Ging-Yuek R Hsiung; Heather Stewart; Anna M Karydas; Elizabeth Finger; Andrew Kertesz; Eileen H Bigio; Sandra Weintraub; Marsel Mesulam; Kimmo J Hatanpaa; Charles L White; Manuela Neumann; Michael J Strong; Thomas G Beach; Zbigniew K Wszolek; Carol Lippa; Richard Caselli; Leonard Petrucelli; Keith A Josephs; Joseph E Parisi; David S Knopman; Ronald C Petersen; Ian R Mackenzie; William W Seeley; Lea T Grinberg; Bruce L Miller; Kevin B Boylan; Neill R Graff-Radford; Bradley F Boeve; Dennis W Dickson; Rosa Rademakers
Journal:  Neurobiol Aging       Date:  2014-05-02       Impact factor: 4.673

Review 6.  SMN regulation in SMA and in response to stress: new paradigms and therapeutic possibilities.

Authors:  Catherine E Dominguez; David Cunningham; Dawn S Chandler
Journal:  Hum Genet       Date:  2017-08-29       Impact factor: 4.132

Review 7.  Targeting angiogenin in therapy of amyotropic lateral sclerosis.

Authors:  Hiroko Kishikawa; David Wu; Guo-fu Hu
Journal:  Expert Opin Ther Targets       Date:  2008-10       Impact factor: 6.902

8.  Genes and Environmental Exposures in Veterans with Amyotrophic Lateral Sclerosis: the GENEVA study. Rationale, study design and demographic characteristics.

Authors:  Silke Schmidt; Kelli D Allen; Valerie T Loiacono; Barbara Norman; Catherine L Stanwyck; Kristina M Nord; Christina D Williams; Edward J Kasarskis; Freya Kamel; Valerie McGuire; Lorene M Nelson; Eugene Z Oddone
Journal:  Neuroepidemiology       Date:  2008-04-18       Impact factor: 3.282

9.  SMN protects cells against mutant SOD1 toxicity by increasing chaperone activity.

Authors:  Tie Zou; Raju Ilangovan; Furong Yu; Zuoshang Xu; Jianhua Zhou
Journal:  Biochem Biophys Res Commun       Date:  2007-10-25       Impact factor: 3.575

10.  Genome-wide association reveals three SNPs associated with sporadic amyotrophic lateral sclerosis through a two-locus analysis.

Authors:  Qiuying Sha; Zhaogong Zhang; Jennifer C Schymick; Bryan J Traynor; Shuanglin Zhang
Journal:  BMC Med Genet       Date:  2009-09-09       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.